The COVID-19 pandemic has had a significant impact worldwide particularly among those who are immunocompromised. Numerous studies have highlighted the increased risk of acute SARS-CoV-2 infection among patients with rheumatic diseases (RD).
All News
Article
Article
The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of these scientific posters.
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Article
Undiagnosed RA During the Pandemic
EurekAlert!
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
Article
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Eric Dein
Tweet
Ab0685 #ACR22 APLS and prior COVID infection
TKR patients at HSS:
1/5 of patients had positive aPL Ab, mostly low level aCL IgM
Not associated with COVID infection or SARS-CoV-2 Ab
@RheumNow https://t.co/HJpnUOrrxc
Please do catch up on my interview with Dr Amit Saxena, New York on their work. #ACR22 Abstr#2081 Breakthrough COVID infection in SLE during Omicron era https://t.co/4dINWSobxj via @YouTube @RheumNow https://t.co/hIHWGRcu5h
Dr. Antoni Chan
Tweet
Getting to know the COVID-19 drugs:
◦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evusheld)
◦ Post-exposure treatments: Paxlovid (po), Molnupiravir (po), Sotrovimab (IV), Remdesivir (IV)
Rachael Perritt, COVID-19, #ACR22 @RheumNow https://t.co/bCwxJ9YfIU
Eric Dein
Tweet
Year in Review #ACR22
Pre-expos PPx for COVID!
Tix-Cil (Evusheld): risk reduction 77%
Cardiac AES 0.6% vs placebo 0.2%
Only 3.3% were on immunosuppression
But Israeli study with immunosuppressed:
92% half as likely to be hospitalized or die
1/2 less infections
@RheumNow
Leonard Calabrese
Tweet
We share our vision of what rheumatologists should be considering thinking and doing regarding COVID-19 in our immunocompromise patients. Would love your reactions @CCalabreseDO @BetsyKirch @DrPujaMehta1 @alhkim @drdavidliew @philipcrobinson #ACR22 https://t.co/OpmoEOXWmL
#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm
Study showing Evusheld can protect our patients who are immunosuppressed; it saved alot of live. One of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/6ekWvA6Ruw
Patricia Harkins
Tweet
Was delighted to be a (very) small part of the fantastic work by the covid GRA getting a special mention by Dr Langford at yr in review #ACR22 @RheumNow
Congrats @RichardPAConway @EBRheum @jeffsparks @SattuiSEMD @rheum_cat 🎉 https://t.co/W0n7rW9pma
Catherine Sims, MD
Tweet
Does #COVID19 #vaccine work in #psoriaticarthritis? @RheumNow #ACR22 Abstract #0389
🤚 HR for infection and hospitalization similar between controls and PsA after 2nd vaccination
🤚#Enbrel (OR 2.39) and #JAKi (OR 9.90) higher risk of infection and hospitalization
FDA issues an Emergency Use Authorization (EUA) for anakinra (Kineret) to treat Hospitalized COVID-19+ Patients with pneumonia requiring supplemental
O2 & ! risk for respiratory failure or increased suPAR levels https://t.co/t5gFULIhCH
12 pts w/ new onset IgA vasculitis (IgAV) post COVID- 19 vaccination (5F; age 52 yrs) - 10 had mRNA & 2 viral vector Vax. Time from Vax to Sxs=11.5 d; 8/12 had vasculitis w/ 1st dose; all skin (7 Jts, 4GI, 2 renal). All Rx w/ steroids https://t.co/eCcUkGeAwV https://t.co/VU1LwFxITC
NY Times reports preprint article showing that taking Paxlovid w/in 5 days of COVID Test+ lowers risk of Long COVID Sxs by 26%. EMR study of 56,340 COVID pts w/ >= risk factor for severe infx; 9,217 Rx w/ Paxlovid had lesss post-Covid Sxs > 90D https://t.co/JyWEoJbUc7 https://t.co/xvTVNugwhJ
The spike protein of SARS-CoV-2 drives NLRP3 inflammasome activation (one of several reasons that patient may flare or activate after COVID-19 infection or vaccination?) https://t.co/92Z14bYaUD https://t.co/iEUSgPghtT
Pre and post-COVID-19 assessment of 78 FM pts by Fibromyalgia Impact Questionnaire-Revised (FIQR). While COVID affected FM pts, there was no statistically significant change in FIQR scores (65% had no improvement or deterioration on FIQR) https://t.co/S1clBCvzWm https://t.co/ZApmgvKM2c
1915 Rheumatic (RMD)pts w/ COVID (42% RA. 15% SLE, 1/2 comorbidities); Outcomes: 28% hospitalized, 8% to ICU & 4% died from COVID-19. Poor COVID-19 outcomes seen w/ age, male, Hi Dz activity, steroids & RTX, & 1+ comorbidity https://t.co/ztBiJc9nxV https://t.co/RVOKyjseFJ
